Amgen Inc
AMGN
View Detailed Chart
342.220USD
-9.100-2.59%
Close 01/28, 16:00（ET）Quotes delayed by 15 min
184.29BMarket Cap
26.28P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-2.59%
5 Days
-0.40%
1 Month
+2.79%
6 Months
+13.58%
Year to Date
+4.56%
1 Year
+22.09%
View Detailed Chart
TradingKey Stock Score of Amgen Inc
Currency: USD Updated: 2026-01-28Key Insights
Amgen Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 20 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 333.79.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Amgen Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Amgen Inc Highlights
StrengthsRisks
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 26.98% year-on-year.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 120.56%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 120.56%.
Fairly Valued
The company’s latest PE is 26.28, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 451.47M shares, increasing 0.01% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 13.71K shares of this stock.
Analyst Rating
Based on
35
analysts
Hold
Current Rating
333.790
Target Price
-3.18%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Amgen Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Amgen Inc Info
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
Ticker SymbolAMGN
CompanyAmgen Inc
CEOBradway (Robert A)
Websitehttps://www.amgen.com/
Related Instruments
-1.51%
+1.46%
-2.35%
-2.49%
-2.86%
-0.95%
-4.07%
-0.89%
-2.42%
+0.79%
-3.62%
-1.69%
-0.91%
-1.38%
-1.06%
-2.61%
0.00%
-2.42%
-1.30%Popular Symbols
256.440
-1.830 (-0.71%)
191.520
+3.000 (+1.59%)
88311.860
-788.770 (-0.89%)
279.700
+27.040 (+10.70%)
2960.580
-49.120 (-1.63%)
431.460
+0.560 (+0.13%)
5551.310
+174.710 (+3.25%)
64.093
+0.876 (+1.39%)
1.199
+0.004 (+0.37%)
152.942
-0.435 (-0.28%)
